Document

0000014272-17-000017.txt : 20170126 0000014272-17-000017.hdr.sgml : 20170126 20170126083524 ACCESSION NUMBER: 0000014272-17-000017 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 4 CONFORMED PERIOD OF REPORT: 20170126 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20170126 DATE AS OF CHANGE: 20170126 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BRISTOL MYERS SQUIBB CO CENTRAL INDEX KEY: 0000014272 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 220790350 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-01136 FILM NUMBER: 17548134 BUSINESS ADDRESS: STREET 1: 345 PARK AVE CITY: NEW YORK STATE: NY ZIP: 10154 BUSINESS PHONE: 2125464000 MAIL ADDRESS: STREET 1: 345 PARK AVE CITY: NEW YORK STATE: NY ZIP: 10154 FORMER COMPANY: FORMER CONFORMED NAME: BRISTOL MYERS CO DATE OF NAME CHANGE: 19891012 8-K 1 q42016earningsrelease8-k.htm 8-K Document

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act Of 1934

Date of Report (Date of earliest event reported): January 26, 2017

BRISTOL-MYERS SQUIBB COMPANY

(Exact Name of Registrant as Specified in its Charter)




Delaware	1-1136	22-0790350
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification Number)

345 Park Avenue

New York, NY 10154

(Address of Principal Executive Office)

Registrant’s telephone number, including area code: (212) 546-4000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):



¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)



¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)



¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))



¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02. Results of Operations and Financial Condition.

On January 26, 2017, Bristol-Myers Squibb Company (the “Company”) issued a press release announcing its financial results for the fourth quarter and twelve months of 2016. A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference. Also furnished and incorporated by reference as Exhibit 99.2 is certain supplemental information posted on the Company’s website at www.bms.com.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.




99.1	Press release of Bristol-Myers Squibb Company dated January 26, 2017.

99.2	Certain supplemental information posted on Bristol-Myers Squibb Company’s website at www.bms.com not included in the press release.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.



	BRISTOL-MYERS SQUIBB COMPANY

Dated: January 26, 2017	By:	/s/ Katherine R. Kelly
	Name:	Katherine R. Kelly
	Title:	Corporate Secretary

EXHIBIT INDEX




Exhibit No.	Description

99.1	Press release of Bristol-Myers Squibb Company dated January 26, 2017.

99.2	Certain supplemental information posted on Bristol-Myers Squibb Company’s website at www.bms.com not included in the press release.

EX-99.1 2 q42016ex991.htm PRESS RELEASE OF BRISTOL-MYERS SQUIBB COMPANY DATED JANUARY 26, 2017 Exhibit

Exhibit 99.1

Bristol-Myers Squibb Reports Fourth Quarter Financial Results


•	Increases Fourth Quarter Revenues 22% to $5.2 Billion, 17% for Full Year to $19.4 Billion


•	Posts Fourth Quarter GAAP EPS of $0.53 and Non-GAAP EPS of $0.63


•	Announces Settlement and License Agreement to Resolve PD-1 Patent Litigation Against Merck


•	Achieves Important Regulatory Milestones for Opdivo


◦	Approved in the U.S. for Metastatic Squamous Cell Carcinoma of the Head and Neck


◦	Approved in Europe for Classical Hodgkin Lymphoma


•	Completes Strategic Transactions in Oncology and Fibrosis


•	Confirms 2017 GAAP EPS Guidance Range of $2.47 to $2.67 and Adjusts Non-GAAP EPS Guidance Range to $2.70 to $2.90

(NEW YORK, January 26, 2017) - Bristol-Myers Squibb Company (NYSE:BMY) today reported results for the fourth quarter and full year of 2016, which were highlighted by strong sales for key products Opdivo and Eliquis, regulatory approvals for Opdivo in the U.S. and Europe, and strategic transactions in oncology and fibrosis that further strengthened the company’s pipeline.

“Bristol-Myers Squibb achieved outstanding operating and financial results in 2016, driven by strong commercial performance across our portfolio,” said Giovanni Caforio, M.D., chief executive officer, Bristol-Myers Squibb. “In 2017, we will continue to advance our pipeline, drive strong commercial execution across the business and progress our broad portfolio of Immuno-Oncology medicines.”



	Fourth Quarter
$ amounts in millions, except per share amounts
	2016		2015			Change
Total Revenues	$	5,243	$	4,287		22	%
GAAP Diluted EPS	0.53		(0.12		)	**
Non-GAAP Diluted EPS	$	0.63	$	0.38		66	%



	Full Year
$ amounts in millions, except per share amounts
	2016		2015		Change
Total Revenues	$	19,427	$	16,560	17	%
GAAP Diluted EPS	2.65		0.93		**
Non-GAAP Diluted EPS	$	2.83	$	2.01	41	%

** In excess of +/- 100%

FOURTH QUARTER FINANCIAL RESULTS


•	Bristol-Myers Squibb posted fourth quarter 2016 revenues of $5.2 billion, an increase of 22% compared to the same period a year ago. Global revenues increased 24% adjusted for foreign exchange impact.


•	U.S. revenues increased 20% to $2.7 billion in the quarter compared to the same period a year ago. International revenues increased 25%. When adjusted for foreign exchange impact, international revenues increased 28%.


•	Gross margin as a percentage of revenue decreased from 77.8% to 73.6% in the quarter primarily due to product mix.


•	Marketing, selling and administrative expenses decreased 3% to $1.5 billion in the quarter.


•	Research and development expenses decreased 27% to $1.4 billion in the quarter due to lower charges resulting from business development transactions and in-process research and development impairments.


•	The effective tax rate was 17.3% in the quarter, compared to a benefit of 54.1% in the fourth quarter last year. Income taxes in both periods include net tax benefits attributed to specified items.

•

The company reported net earnings attributable to Bristol-Myers Squibb of $894 million, or $0.53 per share, in the quarter compared to a net loss of $197 million, or $0.12 per share, a year ago. The results in the fourth quarter of 2015 included per share after tax charges of $0.24 from the Five Prime Therapeutics, Inc. and Cardioxyl Pharmaceuticals, Inc. business development transactions and $0.08 for the transfer of the Erbitux^® business in North America to Eli Lilly and Company.


•	The company reported non-GAAP net earnings attributable to Bristol-Myers Squibb of $1.1 billion, or $0.63 per share, in the fourth quarter, compared to $647 million, or $0.38 per share, for the same period in 2015. An overview of specified items is discussed under the “Use of Non-GAAP Financial Information” section.


•	Cash, cash equivalents and marketable securities were $9.1 billion, with a net cash position of $2.4 billion, as of December 31, 2016.

FOURTH QUARTER PRODUCT AND PIPELINE UPDATE

Product Sales/Business Highlights

Global revenues for the fourth quarter of 2016, compared to the fourth quarter of 2015, were driven by:


•	Opdivo, which grew by $835 million


•	Eliquis, which grew by $346 million or 57% increase


•	Orencia, which grew by 16%


•	Sprycel, which grew by 15%


•	Yervoy, which had sales of $264 million

Opdivo

Litigation


•	In January, the company and Ono Pharmaceutical Company, Ltd. (Ono) announced they signed a global patent license agreement with Merck & Co., Inc. to settle all patent-infringement litigation related to Merck’s PD-1 antibody Keytruda^®. The agreement will result in the dismissal with prejudice of all patent litigation between the companies pertaining to Keytruda^®.

Regulatory


•	In November, the company announced the U.S. Food and Drug Administration (FDA) approved Opdivo for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) with disease progression on or after platinum-based therapy.


•	In November, the company announced the European Commission approved Opdivo for the treatment of patients with relapsed or refractory classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and treatment with brentuximab vedotin.


•	In December, the company and Ono announced Opdivo was approved in Japan for the treatment of patients with relapsed or refractory cHL.


•	In December, the company and Ono announced that Ono submitted a supplemental application for Opdivo for the treatment of unresectable advanced or recurrent gastric cancer.


•	In January, the company announced it decided not to pursue an accelerated regulatory pathway for the regimen of Opdivo plus Yervoy in first-line lung cancer in the U.S. based on a review of data available at this time. Because these are ongoing registrational studies, the company will not be providing additional details.

Clinical


•	In November, the company announced that ONO-4538-12, a Phase 3, randomized, double-blind clinical trial evaluating the efficacy and safety of Opdivo in patients with unresectable advanced or recurrent gastric cancer refractory to, or intolerant of, standard therapy, met its primary endpoint of overall survival. In January, the company announced the results from the trial.


•	In November, at the Society for Immunotherapy of Cancer Annual Meeting, the company announced new data and analysis from studies evaluating urelumab, lirilumab, Opdivo and the Opdivo + Yervoy regimen:


◦	Safety and efficacy data from a Phase 1/2 study of urelumab in combination with Opdivo in patients with hematologic and solid tumors, including biomarker analyses by level of PD-L1 expression.


◦	Interim efficacy analysis, announced by the company and Innate Pharma S.A., from a Phase 1/2 study of the combination of lirilumab and Opdivo in the cohort of advanced platinum refractory squamous cell carcinoma of the head and neck, including exploratory biomarker analyses of patient response by level of PD-L1 expression.


◦	CheckMate -032: Results from cohorts of the Phase 1/2 open-label trial investigating two combination schedules of Opdivo plus Yervoy in patients with locally advanced or metastatic urothelial carcinoma previously treated with platinum-based therapy.


•	In December, at the International Association for the Study of Lung Cancer World Conference on Lung Cancer, the company announced new data from studies evaluating Opdivo and the Opdivo + Yervoy regimen:


◦	Checkmate -012: Updated findings from the Phase 1b trial in chemotherapy-naïve advanced non-small cell lung cancer patients evaluating Opdivo monotherapy, or in combination with Yervoy at different doses and schedules.


◦	CheckMate -032: Updated results for Opdivo monotherapy and in combination with Yervoy in previously treated small cell lung cancer patients, a cohort of the Phase 1/2 open-label trial.


•	In December, during the American Society of Hematology Annual Meeting, the company and Seattle Genetics announced the first reported data from an ongoing Phase 1/2 clinical trial evaluating Adcetris^® (brentuximab vedotin) in combination with Opdivo in relapsed or refractory cHL.

FOURTH QUARTER BUSINESS DEVELOPMENT UPDATE

•

In November, the company and Enterome announced a collaboration agreement for the discovery and development of microbiome-derived biomarkers, drug targets and bioactive molecules to be developed as potential companion diagnostics and therapeutics for cancer. Additionally, the collaboration will seek to identify novel microbiome-derived biomarkers in an effort to improve clinical outcomes for patients treated with Bristol-Myers Squibb’s Immuno-Oncology portfolio.


•	In November, the company and Infinity Pharmaceuticals announced a clinical trial collaboration to evaluate Bristol-Myers Squibb’s Opdivo in combination with Infinity’s IPI-549 in patients with advanced solid tumors.

•

In November, the company and Nitto Denko Corporation (Nitto) announced an agreement granting Bristol-Myers Squibb exclusive worldwide rights for the development and commercialization of Nitto’s investigational siRNA molecules targeting heat shock protein 47 (HSP47) in vitamin A containing formulations, which includes Nitto’s lead asset ND-L02-s0201, currently in Phase 1b study for the treatment of advanced liver fibrosis. The agreement also grants Bristol-Myers Squibb the option to receive exclusive licenses for HSP47 siRNAs in vitamin A containing formulations for the treatment of lung fibrosis and other organ fibrosis.


•	In November, the company announced a five-year research collaboration with the Johns Hopkins University designed to identify mechanisms of response and resistance in patients whose cancer is being treated with checkpoint inhibitor-based immunotherapies, including Opdivo monotherapy, or Opdivo in combination with Yervoy or other investigational immunotherapies.


•	In December, the company and PsiOxus Therapeutics, Ltd. announced an agreement granting Bristol-Myers Squibb exclusive worldwide rights to NG-348, a pre-clinical stage, “armed” oncolytic virus with the goal of addressing solid tumors.


•	In December, the company and Calithera Biosciences announced a clinical collaboration to evaluate Opdivo in combination with CB-839 in clear cell renal cell carcinoma.


•	In January, the company announced a new clinical research collaboration to evaluate the combination of Opdivo and Janssen’s CD38-directed cytolytic antibody Darzalex^® in Phase 1b/2 clinical studies in multiple myeloma and solid tumors including non-small cell lung cancer, pancreatic cancer, colorectal cancer , triple negative breast cancer and head and neck cancer.


•	In January, the company and GeneCentric Diagnostics, Inc. announced a research collaboration to explore whether the application of GeneCentric’s Cancer Subtype Platform (CSP) might be able to identify translational biomarkers for Opdivo. Additionally, GeneCentric announced it had secured equity funding from the company to support the clinical development of its CSP and new research laboratory.

2017 FINANCIAL GUIDANCE

Bristol-Myers Squibb is confirming its 2017 GAAP EPS guidance range of $2.47 - $2.67 and is adjusting its non-GAAP EPS guidance range from $2.85 - $3.05 to $2.70 - $2.90. Both GAAP and non-GAAP guidance assume current exchange rates. 2017 GAAP and non-GAAP line-item guidance assumptions include:


•	Worldwide revenues increasing in the low-single digits.


•	Gross margin as a percentage of revenue to be approximately 72% to 73% for both GAAP and non-GAAP.


•	Marketing, selling and administrative expenses decreasing in the mid- to high-single digit range for both GAAP and non-GAAP.


•	Research and development expenses increasing in the high-single digit range for both GAAP and non-GAAP.


•	An effective tax rate of approximately 21% for both GAAP and non-GAAP.

As previously announced in the third quarter of 2016, the company’s operating model is evolving, to drive the company’s continued success in the near- and long-term. The majority of costs are expected to be incurred by 2020. Although GAAP operating expenses may increase initially as restructuring and other charges are incurred relating to this evolution, the company expects non-GAAP operating expenses to be roughly flat with 2016 levels through 2020.

The financial guidance excludes the impact of any potential future strategic acquisitions and divestitures and any specified items that have not yet been identified and quantified. The guidance also assumes no generic entry for Sprycel in Europe following the appeal of the European Patent Office’s decision. The non-GAAP guidance also excludes other specified items as discussed under “Use of Non-GAAP Financial Information.” Details reconciling GAAP amounts to non-GAAP amounts, with non-GAAP reflecting specified items are provided in supplemental materials attached to this press release and available on the company’s website.

Erbitux^® is a trademark of ImClone LLC.

Keytruda^®is a trademark of Merck & Co., Inc.

Adcetris^® is a trademark of Seattle Genetics, Inc.

Darzalex^® is a trademark of Janssen Biotech, Inc.

Use of Non-GAAP Financial Information

This press release contains non-GAAP financial measures, including non-GAAP earnings and related EPS information, that are adjusted to exclude certain costs, expenses, gains and losses and other specified items that are evaluated on an individual basis. These items are adjusted after considering their quantitative and qualitative aspects and typically have one or more of the following characteristics, such as being highly variable, difficult to project, unusual in nature, significant to the results of a particular period or not indicative of future operating results. Similar charges or gains were recognized in prior periods and will likely reoccur in future periods including restructuring costs, accelerated depreciation and impairment of property, plant and equipment and intangible assets, R&D charges in connection with the acquisition or licensing of third party intellectual property rights, divestiture gains or losses, pension, legal and other contractual settlement charges and debt redemption gains or losses, among other items. Deferred and current income taxes attributed to these items are also adjusted for considering their individual impact to the overall tax expense, deductibility and jurisdictional tax rates. Non-GAAP information is intended to portray the results of our baseline performance, supplement or enhance management, analysts and investors overall understanding of our underlying financial performance and facilitate comparisons among current, past and future periods. For example, non-GAAP earnings and EPS information is an indication of our baseline performance before items that are considered by us to not be reflective of our ongoing results. In addition, this information is among the primary indicators we use as a basis for evaluating performance, allocating resources, setting incentive compensation targets and planning and forecasting for future periods. This information is not intended to be considered in isolation or as a substitute for net earnings or diluted EPS prepared in accordance with GAAP.

Statement on Cautionary Factors

This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding, among other things, statements relating to goals, plans and projections regarding the company’s financial position, results of operations, market position, product development and business strategy. These statements may be identified by the fact that they use words such as "anticipate", "estimates", "should", "expect", "guidance", "project", "intend", "plan", "believe" and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations.

These factors include, among other things, effects of the continuing implementation of governmental laws and regulations related to Medicare, Medicaid, Medicaid managed care organizations and entities under the Public Health Service 340B program, pharmaceutical rebates and reimbursement, market factors, competitive product development and approvals, pricing controls and pressures (including changes in rules and practices of managed care groups and institutional and governmental purchasers), economic conditions such as interest rate and currency exchange rate fluctuations, judicial decisions, claims and concerns that may arise regarding the safety and efficacy of in-line products and product candidates, changes to wholesaler inventory levels, variability in data provided by third parties, changes in, and interpretation of, governmental regulations and legislation affecting domestic or foreign operations, including tax obligations, changes to business or tax planning strategies, difficulties and delays in product development, manufacturing or sales including any potential future recalls, patent positions and the ultimate outcome of any litigation matter. These factors also include the company’s ability to execute successfully its strategic plans, including its business development strategy, the expiration of patents or data protection on certain products, including assumptions about the company’s ability to retain patent exclusivity of certain products, and the impact and result of governmental investigations. There can be no guarantees with respect to pipeline products that future clinical studies will support the data described in this release, that the compounds will receive necessary regulatory approvals, or that they will prove to be commercially successful; nor are there guarantees that regulatory approvals will be sought, or sought within currently expected timeframes, or that contractual milestones will be achieved. For further details and a discussion of these and other risks and uncertainties, see the company's periodic reports, including the annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Company and Conference Call Information

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol-Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube and Facebook.

There will be a conference call on January 26, 2017 at 10:30 a.m. EST during which company executives will review financial information and address inquiries from investors and analysts. Investors and the general public are invited to listen to a live webcast of the call at http://investor.bms.com or by calling the U.S. toll free 877-201-0168 or international 647-788-4901, confirmation code: 60705823. Materials related to the call will be available at the same website prior to the conference call. A replay of the call will be available beginning at 1:30 p.m. EST on January 26, 2017 through 11:59 p.m. EST on February 9, 2017. The replay will also be available through http://investor.bms.com or by calling the U.S. toll free 855-859-2056 or international 404-537-3406, confirmation code: 60705823.

For more information, contact: Ken Dominski, 609-252-5251, ken.dominski@bms.com, Communications; John Elicker, 609-252-4611, john.elicker@bms.com, or Bill Szablewski, 609-252-5894, william.szablewski@bms.com, Investor Relations.

BRISTOL-MYERS SQUIBB COMPANY

PRODUCT REVENUE

FOR THE THREE MONTHS ENDED DECEMBER 31, 2016 AND 2015

(Unaudited, dollars in millions)



	Worldwide Revenues						U.S. Revenues
	2016		2015		% Change		2016		2015		% Change
Three Months Ended December 31,
Key Products
Oncology
Empliciti	$	47	$	3	**		$	36	$	3	**
Erbitux^(a)	—		—		—		—		—		—
Opdivo	1,310		475		**		715		410		74	%
Sprycel	494		429		15	%	267		228		17	%
Yervoy	264		265		—		202		164		23	%
Cardiovascular
Eliquis	948		602		57	%	539		335		61	%
Immunoscience
Orencia	625		540		16	%	423		372		14	%
Virology
Baraclude	296		309		(4	)%	17		27		(37	)%
Hepatitis C Franchise	226		458		(51	)%	82		212		(61	)%
Reyataz Franchise	206		272		(24	)%	117		142		(18	)%
Sustiva Franchise	246		312		(21	)%	212		269		(21	)%
Neuroscience
Abilify^(b)	31		39		(21	)%	—		7		(100	)%

Mature Products and All Other	550		583		(6	)%	95		94		1	%

Total	$	5,243	$	4,287	22	%	$	2,705	$	2,263	20	%



**	In excess of +/- 100%

(a)	Erbitux is a trademark of ImClone LLC. ImClone LLC is a wholly-owned subsidiary of Eli Lilly and Company.
(b)	Abilify is a trademark of Otsuka Pharmaceutical Co., Ltd.

BRISTOL-MYERS SQUIBB COMPANY

PRODUCT REVENUE

FOR THE TWELVE MONTHS ENDED DECEMBER 31, 2016 AND 2015

(Unaudited, dollars in millions)



	Worldwide Revenues						U.S. Revenues
	2016		2015		% Change		2016		2015		% Change
Twelve Months Ended December 31,
Key Products
Oncology
Empliciti	$	150	$	3	**		$	133	$	3	**
Erbitux	—		501		(100	)%	—		487		(100	)%
Opdivo	3,774		942		**		2,664		823		**
Sprycel	1,824		1,620		13	%	969		829		17	%
Yervoy	1,053		1,126		(6	)%	802		602		33	%
Cardiovascular
Eliquis	3,343		1,860		80	%	1,963		1,023		92	%
Immunoscience
Orencia	2,265		1,885		20	%	1,532		1,271		21	%
Virology
Baraclude	1,192		1,312		(9	)%	66		135		(51	)%
Hepatitis C Franchise	1,578		1,603		(2	)%	827		323		**
Reyataz Franchise	912		1,139		(20	)%	484		591		(18	)%
Sustiva Franchise	1,065		1,252		(15	)%	901		1,041		(13	)%
Neuroscience
Abilify	128		746		(83	)%	—		600		(100	)%

Mature Products and All Other	2,143		2,571		(17	)%	379		460		(18	)%

Total	$	19,427	$	16,560	17	%	$	10,720	$	8,188	31	%



**	In excess of +/- 100%

BRISTOL-MYERS SQUIBB COMPANY

CONSOLIDATED STATEMENTS OF EARNINGS

FOR THE THREE AND TWELVE MONTHS ENDED DECEMBER 31, 2016 AND 2015

(Unaudited, dollars and shares in millions except per share data)



	Three Months Ended December 31,						Twelve Months Ended December 31,
	2016			2015			2016			2015
Net product sales	$	4,814		$	3,862		$	17,702		$	14,045
Alliance and other revenues	429			425			1,725			2,515
Total Revenues	5,243			4,287			19,427			16,560

Cost of products sold	1,383			952			4,946			3,909
Marketing, selling and administrative	1,461			1,501			4,911			4,841
Research and development	1,400			1,916			4,940			5,920
Other (income)/expense	(87		)	328			(1,285		)	(187		)
Total Expenses	4,157			4,697			13,512			14,483

Earnings/(Loss) Before Income Taxes	1,086			(410		)	5,915			2,077
Provision for/(Benefit from) Income Taxes	188			(222		)	1,408			446

Net Earnings/(Loss)	898			(188		)	4,507			1,631
Net Earnings Attributable to Noncontrolling Interest	4			9			50			66
Net Earnings/(Loss) Attributable to BMS	$	894		$	(197	)	$	4,457		$	1,565

Average Common Shares Outstanding:
Basic	1,672			1,669			1,671			1,667
Diluted	1,680			1,669			1,680			1,679

Earnings/(Loss) per Common Share
Basic	$	0.53		$	(0.12	)	$	2.67		$	0.94
Diluted	$	0.53		$	(0.12	)	$	2.65		$	0.93

Other (Income)/Expense
Interest expense	$	40		$	43		$	167		$	184
Investment income	(24		)	(27		)	(105		)	(101		)
Provision for restructuring	68			68			109			118
Litigation and other settlements	(1		)	145			47			159
Equity in net income of affiliates	(12		)	(16		)	(77		)	(83		)
Divestiture (gains)/losses	(2		)	174			(576		)	(196		)
Royalties and licensing income	(140		)	(125		)	(719		)	(383		)
Transition and other service fees	(54		)	(31		)	(238		)	(122		)
Pension charges	25			49			91			160
Intangible asset impairment	—			—			15			13
Equity investment impairment	—			—			45			—
Written option adjustment	—			—			—			(123		)
Loss on debt redemption	—			—			—			180
Other	13			48			(44		)	7
Other (income)/expense	$	(87	)	$	328		$	(1,285	)	$	(187	)

BRISTOL-MYERS SQUIBB COMPANY

SPECIFIED ITEMS

FOR THE THREE AND TWELVE MONTHS ENDED DECEMBER 31, 2016 AND 2015

(Unaudited, dollars in millions)



	Three Months Ended December 31,						Twelve Months Ended December 31,
	2016			2015			2016			2015
Cost of products sold^(a)	$	6		$	10		$	21		$	84

Marketing, selling and administrative	—			4			—			10

License and asset acquisition charges	130			554			439			1,679
IPRD impairments	13			160			13			160
Accelerated depreciation and other	43			27			83			44
Research and development	186			741			535			1,883

Provision for restructuring	68			65			109			115
Divestiture (gains)/losses	—			171			(559		)	(187		)
Pension charges	25			49			91			160
Written option adjustment	—			—			—			(123		)
Litigation and other settlements	—			143			40			158
Intangible asset impairment	—			—			15			13
Loss on debt redemption	—			—			—			180
Royalties and licensing income	(10		)	—			(10		)	—
Other (income)/expense	83			428			(314		)	316

Increase to pretax income	275			1,183			242			2,293

Income tax on items above	(105		)	(339		)	51			(480		)

Increase to net earnings	$	170		$	844		$	293		$	1,813



(a)	Specified items in cost of products sold are accelerated depreciation, asset impairment and other shutdown costs.

BRISTOL-MYERS SQUIBB COMPANY

RECONCILIATION OF CERTAIN GAAP LINE ITEMS TO CERTAIN NON-GAAP LINE ITEMS

FOR THE THREE AND TWELVE MONTHS ENDED DECEMBER 31, 2016 AND 2015

(Unaudited, dollars in millions)



	Three Months Ended December 31, 2016									Twelve Months Ended December 31, 2016
	GAAP			Specified Items^(a)			Non- GAAP			GAAP			Specified Items^(a)			Non- GAAP
Gross Profit	$	3,860		$	6		$	3,866		$	14,481		$	21		$	14,502
Marketing, selling and administrative	1,461			—			1,461			4,911			—			4,911
Research and development	1,400			(186		)	1,214			4,940			(535		)	4,405
Other (income)/expense	(87		)	(83		)	(170		)	(1,285		)	314			(971		)
Earnings Before Income Taxes	1,086			275			1,361			5,915			242			6,157
Provision for Income Taxes	188			(105		)	293			1,408			51			1,357

Net Earnings Attributable to BMS used for Diluted EPS Calculation	$	894		$	170		$	1,064		$	4,457		$	293		$	4,750

Average Common Shares Outstanding - Diluted	1,680			1,680			1,680			1,680			1,680			1,680
Diluted Earnings Per Share	$	0.53		$	0.10		$	0.63		$	2.65		$	0.18		$	2.83

Effective Tax Rate	17.3		%	4.2		%	21.5		%	23.8		%	(1.8		)%	22.0		%

	Three Months Ended December 31, 2015									Twelve Months Ended December 31, 2015
	GAAP			Specified Items^(a)			Non- GAAP			GAAP			Specified Items^(a)			Non- GAAP
Gross Profit	$	3,335		$	10		$	3,345		$	12,651		$	84		$	12,735
Marketing, selling and administrative	1,501			(4		)	1,497			4,841			(10		)	4,831
Research and development	1,916			(741		)	1,175			5,920			(1,883		)	4,037
Other (income)/expense	328			(428		)	(100		)	(187		)	(316		)	(503		)
Earnings/(Loss) Before Income Taxes	(410		)	1,183			773			2,077			2,293			4,370
Provision for/(Benefit from) Income Taxes	(222		)	(339		)	117			446			(480		)	926

Net Earnings/(Loss) Attributable to BMS used for Diluted EPS Calculation	$	(197	)	$	844		$	647		$	1,565		$	1,813		$	3,378

Average Common Shares Outstanding - Diluted^(b)	1,669			1,681			1,681			1,679			1,679			1,679
Diluted Earnings/(Loss) Per Share	$	(0.12	)	$	0.50		$	0.38		$	0.93		$	1.08		$	2.01

Effective Tax Rate	54.1		%	(39.0		)%	15.1		%	21.5		%	(0.3		)%	21.2		%



(a)	Refer to the Specified Items schedule for further details. Effective tax rate on the Specified Items represents the difference between the GAAP and Non-GAAP effective tax rate.
(b)	Difference between GAAP and Non-GAAP Diluted Shares Outstanding for the three months ended December 31, 2015 relates to incremental shares attributable to share-based compensation plans.

BRISTOL-MYERS SQUIBB COMPANY

NET CASH/(DEBT) CALCULATION

AS OF DECEMBER 31, 2016 AND SEPTEMBER 30, 2016

(Unaudited, dollars in millions)



	December 31, 2016			September 30, 2016
Cash and cash equivalents	$	4,237		$	3,432
Marketable securities - current	2,113			2,128
Marketable securities - non-current	2,719			3,035
Cash, cash equivalents and marketable securities	9,069			8,595
Short-term borrowings and current portion of long-term debt	(992		)	(990		)
Long-term debt	(5,716		)	(5,836		)
Net cash position	$	2,361		$	1,769

EX-99.2 3 q42016ex992.htm CERTAIN SUPPLEMENTAL INFORMATION Exhibit

Exhibit 99.2

BRISTOL-MYERS SQUIBB COMPANY

QUARTERLY TREND ANALYSIS OF REVENUES

(Unaudited, dollars in millions)



Revenues	2015																					2016																					% Change		FX Impact
	1st Qtr			2nd Qtr			6 Months			3rd Qtr			9 Months			4th Qtr			Year			1st Qtr			2nd Qtr			6 Months			3rd Qtr			9 Months			4th Qtr			Year			Qtr vs. Qtr	YTD vs. YTD	Qtr vs. Qtr	YTD vs. YTD
United States	$	2,044		$	1,837		$	3,881		$	2,044		$	5,925		$	2,263		$	8,188		$	2,537		$	2,688		$	5,225		$	2,790		$	8,015		$	2,705		$	10,720		20%	31%	—	—
Europe	782			974			1,756			813			2,569			922			3,491			870			1,039			1,909			946			2,855			1,360			4,215			48%	21%	(3)%	(2)%
Rest of the World	1,019			1,124			2,143			1,027			3,170			972			4,142			840			1,013			1,853			1,069			2,922			1,042			3,964			7%	(4)%	(3)%	(4)%
Other	196			228			424			185			609			130			739			144			131			275			117			392			136			528			5%	(29)%	N/A	N/A
Total	$	4,041		$	4,163		$	8,204		$	4,069		$	12,273		$	4,287		$	16,560		$	4,391		$	4,871		$	9,262		$	4,922		$	14,184		$	5,243		$	19,427		22%	17%	(2)%	(2)%

% of Revenues	2015																					2016
	1st Qtr			2nd Qtr			6 Months			3rd Qtr			9 Months			4th Qtr			Year			1st Qtr			2nd Qtr			6 Months			3rd Qtr			9 Months			4th Qtr			Year
United States	50.6		%	44.1		%	47.3		%	50.2		%	48.3		%	52.8		%	49.4		%	57.8		%	55.2		%	56.4		%	56.7		%	56.5		%	51.6		%	55.2		%
Europe	19.4		%	23.4		%	21.4		%	20.0		%	20.9		%	21.5		%	21.1		%	19.8		%	21.3		%	20.6		%	19.2		%	20.1		%	25.9		%	21.7		%
Rest of the World	25.2		%	27.0		%	26.1		%	25.2		%	25.8		%	22.7		%	25.0		%	19.1		%	20.8		%	20.0		%	21.7		%	20.6		%	19.9		%	20.4		%
Other	4.8		%	5.5		%	5.2		%	4.6		%	5.0		%	3.0		%	4.5		%	3.3		%	2.7		%	3.0		%	2.4		%	2.8		%	2.6		%	2.7		%
Total	100.0		%	100.0		%	100.0		%	100.0		%	100.0		%	100.0		%	100.0		%	100.0		%	100.0		%	100.0		%	100.0		%	100.0		%	100.0		%	100.0		%

BRISTOL-MYERS SQUIBB COMPANY

EARNINGS FROM OPERATIONS

(Unaudited, dollars and shares in millions except per share data)



	2015																					2016																					% Change
	1st Qtr			2nd Qtr			6 Months			3rd Qtr			9 Months			4th Qtr			Year			1st Qtr			2nd Qtr			6 Months			3rd Qtr			9 Months			4th Qtr			Year			Qtr vs. Qtr		YTD vs. YTD
Net product sales	$	3,059		$	3,572		$	6,631		$	3,552		$	10,183		$	3,862		$	14,045		$	3,964		$	4,432		$	8,396		$	4,492		$	12,888		$	4,814		$	17,702		25%		26%
Alliance and other revenues	982			591			1,573			517			2,090			425			2,515			427			439			866			430			1,296			429			1,725			1%		(31)%
Total Revenues	$	4,041		$	4,163		$	8,204		$	4,069		$	12,273		$	4,287		$	16,560		$	4,391		$	4,871		$	9,262		$	4,922		$	14,184		$	5,243		$	19,427		22%		17%

Cost of products sold	847			1,013			1,860			1,097			2,957			952			3,909			1,052			1,206			2,258			1,305			3,563			1,383			4,946			45%		27%
Marketing, selling and administrative	1,029			1,135			2,164			1,176			3,340			1,501			4,841			1,068			1,238			2,306			1,144			3,450			1,461			4,911			(3)%		1%
Research and development	1,016			1,856			2,872			1,132			4,004			1,916			5,920			1,136			1,266			2,402			1,138			3,540			1,400			4,940			(27)%		(17)%
Other (income)/expense	(299		)	107			(192		)	(323		)	(515		)	328			(187		)	(520		)	(454		)	(974		)	(224		)	(1,198		)	(87		)	(1,285		)	**		**
Total Expenses	2,593			4,111			6,704			3,082			9,786			4,697			14,483			2,736			3,256			5,992			3,363			9,355			4,157			13,512			(11)%		(7)%

Earnings/(Loss) Before Income Taxes	$	1,448		$	52		$	1,500		$	987		$	2,487		$	(410	)	$	2,077		$	1,655		$	1,615		$	3,270		$	1,559		$	4,829		$	1,086		$	5,915		**		**
Provision for/(Benefit from) Income Taxes	249			162			411			257			668			(222		)	446			449			427			876			344			1,220			188			1,408			**		**
Net Earnings/(Loss)	$	1,199		$	(110	)	$	1,089		$	730		$	1,819		$	(188	)	$	1,631		$	1,206		$	1,188		$	2,394		$	1,215		$	3,609		$	898		$	4,507		**		**
Net Earnings Attributable to Noncontrolling Interest	13			20			33			24			57			9			66			11			22			33			13			46			4			50			(56)%		(24)%
Net Earnings/(Loss) Attributable to BMS	$	1,186		$	(130	)	$	1,056		$	706		$	1,762		$	(197	)	$	1,565		$	1,195		$	1,166		$	2,361		$	1,202		$	3,563		$	894		$	4,457		**		**

Diluted Earnings/(Loss) per Common Share*	$	0.71		$	(0.08	)	$	0.63		$	0.42		$	1.05		$	(0.12	)	$	0.93		$	0.71		$	0.69		$	1.41		$	0.72		$	2.12		$	0.53		$	2.65		**		**
Average Common Shares Outstanding - Diluted	1,676			1,667			1,677			1,678			1,677			1,669			1,679			1,680			1,679			1,679			1,679			1,679			1,680			1,680			1%		—
Dividends declared per common share	$	0.37		$	0.37		$	0.74		$	0.37		$	1.11		$	0.38		$	1.49		$	0.38		$	0.38		$	0.76		$	0.38		$	1.14		$	0.39		$	1.53		3%		3%


	2015																					2016
% of Total Revenues	1st Qtr			2nd Qtr			6 Months			3rd Qtr			9 Months			4th Qtr			Year			1st Qtr			2nd Qtr			6 Months			3rd Qtr			9 Months			4th Qtr			Year
Gross Margin	79.0		%	75.7		%	77.3		%	73.0		%	75.9		%	77.8		%	76.4		%	76.0		%	75.2		%	75.6		%	73.5		%	74.9		%	73.6		%	74.5		%

Other Ratios
Effective tax rate	17.2		%	311.5		%	27.4		%	26.0		%	26.9		%	54.1		%	21.5		%	27.1		%	26.4		%	26.8		%	22.1		%	25.3		%	17.3		%	23.8		%

Other (Income)/Expense	2015																					2016																					% Change
	1st Qtr			2nd Qtr			6 Months			3rd Qtr			9 Months			4th Qtr			Year			1st Qtr			2nd Qtr			6 Months			3rd Qtr			9 Months			4th Qtr			Year			Qtr vs. Qtr		YTD vs. YTD
Interest expense	$	51		$	49		$	100		$	41		$	141		$	43		$	184		$	43		$	42		$	85		$	42		$	127		$	40		$	167		(7	)%	(9	)%
Investment income	(30		)	(26		)	(56		)	(18		)	(74		)	(27		)	(101		)	(24		)	(25		)	(49		)	(32		)	(81		)	(24		)	(105		)	(11	)%	4	%
Provision for restructuring	12			28			40			10			50			68			118			4			18			22			19			41			68			109			—		(8	)%
Litigation and other settlements	12			4			16			(2		)	14			145			159			43			6			49			(1		)	48			(1		)	47			**		(70	)%
Equity in net income of affiliates	(26		)	(22		)	(48		)	(19		)	(67		)	(16		)	(83		)	(26		)	(20		)	(46		)	(19		)	(65		)	(12		)	(77		)	(25	)%	(7	)%
Divestiture (gains)/losses	(154		)	(8		)	(162		)	(208		)	(370		)	174			(196		)	(270		)	(283		)	(553		)	(21		)	(574		)	(2		)	(576		)	**		**
Royalties and licensing income	(98		)	(97		)	(195		)	(63		)	(258		)	(125		)	(383		)	(254		)	(167		)	(421		)	(158		)	(579		)	(140		)	(719		)	12	%	88	%
Transition and other service fees	(27		)	(27		)	(54		)	(37		)	(91		)	(31		)	(122		)	(53		)	(74		)	(127		)	(57		)	(184		)	(54		)	(238		)	74	%	95	%
Pension charges	27			36			63			48			111			49			160			22			25			47			19			66			25			91			(49	)%	(43	)%
Intangible asset impairment	13			—			13			—			13			—			13			15			—			15			—			15			—			15			—		15	%
Equity investment impairment	—			—			—			—			—			—			—			—			45			45			—			45			—			45			—		N/A
Written option adjustment	(36		)	—			(36		)	(87		)	(123		)	—			(123		)	—			—			—			—			—			—			—			—		(100	)%
Loss on debt redemption	—			180			180			—			180			—			180			—			—			—			—			—			—			—			—		(100	)%
Other	(43		)	(10		)	(53		)	12			(41		)	48			7			(20		)	(21		)	(41		)	(16		)	(57		)	13			(44		)	(73	)%	**
	$	(299	)	$	107		$	(192	)	$	(323	)	$	(515	)	$	328		$	(187	)	$	(520	)	$	(454	)	$	(974	)	$	(224	)	$	(1,198	)	$	(87	)	$	(1,285	)	**		**

Quarterly amounts may not add to the year-to-date totals due to rounding of individual calculations.

In excess of +/- 100%

BRISTOL-MYERS SQUIBB COMPANY

RECONCILIATION OF GAAP AND NON-GAAP GROWTH DOLLARS AND PERCENTAGES EXCLUDING FOREIGN EXCHANGE IMPACT

FOR THE PERIOD ENDED DECEMBER 31, 2016

(Unaudited, dollars in millions)



QUARTER-TO-DATE	2016			2015			Growth $			Growth %	Favorable / (Unfavorable) FX Impact $ *			2016 Excluding FX		Favorable / (Unfavorable) FX Impact % *	Growth % Excluding FX
Revenues	$	5,243		$	4,287		$	956		22%	$	(60	)	$	5,303	(2)%	24%
Gross profit	3,860			3,335			525			16%	N/A			N/A		N/A	N/A
Gross profit excluding specified items^(a)	3,866			3,345			521			16%	N/A			N/A		N/A	N/A
Gross profit excluding specified items as a % of revenues	73.7		%	78.0		%

Marketing, selling and administrative	1,461			1,501			(40		)	(3)%	31			1,492		2%	(1)%
Marketing, selling and administrative excluding specified items^(a)	1,461			1,497			(36		)	(2)%	31			1,492		2%	—

MS&A excluding specified items as a % of revenues	27.9		%	34.9		%

Research and development	1,400			1,916			(516		)	(27)%	7			1,407		—	(27)%
Research and development excluding specified items^(a)	1,214			1,175			39			3%	8			1,222		1%	4%

Research and development excluding specified items as a % of revenues	23.2		%	27.4		%

YEAR-TO-DATE	2016			2015			Growth $			Growth %	Favorable / (Unfavorable) FX Impact $ *			2016 Excluding FX		Favorable / (Unfavorable) FX Impact % *	Growth % Excluding FX
Revenues	$	19,427		$	16,560		$	2,867		17%	$	(237	)	$	19,664	(2)%	19%
Gross profit	14,481			12,651			1,830			14%	N/A			N/A		N/A	N/A
Gross profit excluding specified items^(a)	14,502			12,735			1,767			14%	N/A			N/A		N/A	N/A
Gross profit excluding specified items as a % of revenues	74.6		%	76.9		%

Marketing, selling and administrative	4,911			4,841			70			1%	80			4,991		2%	3%
Marketing, selling and administrative excluding specified items^(a)	4,911			4,831			80			2%	80			4,991		1%	3%

MS&A excluding specified items as a % of revenues	25.3		%	29.2		%

Research and development	4,940			5,920			(980		)	(17)%	19			4,959		1%	(16)%
Research and development excluding specified items^(a)	4,405			4,037			368			9%	20			4,425		1%	10%

Research and development excluding specified items as a % of revenues	22.7		%	24.4		%

(a)

Refer to the Specified Items schedule for further details.

Foreign exchange impacts were derived by applying the prior period average currency rates to the current period sales and expenses.

BRISTOL-MYERS SQUIBB COMPANY

WORLDWIDE REVENUES

QUARTERLY REVENUES TREND ANALYSIS

(Unaudited, dollars in millions)



	2015														2016														Growth $						% Change
	1st Qtr		2nd Qtr		6 Months		3rd Qtr		9 Months		4th Qtr		Year		1st Qtr		2nd Qtr		6 Months		3rd Qtr		9 Months		4th Qtr		Year		Qtr vs. Qtr			YTD vs. YTD			Qtr vs. Qtr		YTD vs. YTD
Oncology^(a)
Empliciti	$	—	$	—	$	—	$	—	$	—	$	3	$	3	$	28	$	34	$	62	$	41	$	103	$	47	$	150	$	44		$	147		**		**
Erbitux	165		169		334		167		501		—		501		—		—		—		—		—		—		—		—			(501		)	—		(100	)%
Opdivo	40		122		162		305		467		475		942		704		840		1,544		920		2,464		1,310		3,774		835			2,832			**		**
Sprycel	375		405		780		411		1,191		429		1,620		407		451		858		472		1,330		494		1,824		65			204			15	%	13	%
Yervoy	325		296		621		240		861		265		1,126		263		241		504		285		789		264		1,053		(1		)	(73		)	—		(6	)%
Cardiovascular^(a)
Eliquis	355		437		792		466		1,258		602		1,860		734		777		1,511		884		2,395		948		3,343		346			1,483			57	%	80	%
Immunoscience^(a)
Orencia^(b)	400		461		861		484		1,345		540		1,885		475		593		1,068		572		1,640		625		2,265		85			380			16	%	20	%
Virology^(a)
Baraclude	340		343		683		320		1,003		309		1,312		291		299		590		306		896		296		1,192		(13		)	(120		)	(4	)%	(9	)%
Hepatitis C Franchise^(c)	264		479		743		402		1,145		458		1,603		427		546		973		379		1,352		226		1,578		(232		)	(25		)	(51	)%	(2	)%
Reyataz Franchise	294		303		597		270		867		272		1,139		221		247		468		238		706		206		912		(66		)	(227		)	(24	)%	(20	)%
Sustiva Franchise^(d)	290		317		607		333		940		312		1,252		273		271		544		275		819		246		1,065		(66		)	(187		)	(21	)%	(15	)%
Neuroscience^(a)
Abilify^(e)	554		107		661		46		707		39		746		33		35		68		29		97		31		128		(8		)	(618		)	(21	)%	(83	)%

Mature Products and All Other^(f)	639		724		1,363		625		1,988		583		2,571		535		537		1,072		521		1,593		550		2,143		(33		)	(428		)	(6	)%	(17	)%

Total	$	4,041	$	4,163	$	8,204	$	4,069	$	12,273	$	4,287	$	16,560	$	4,391	$	4,871	$	9,262	$	4,922	$	14,184	$	5,243	$	19,427	$	956		$	2,867		22	%	17	%



**	In excess of +/- 100%
(a)	Key products listed do not represent all products in the respective therapeutic areas.
(b)	Includes Orencia SubQ revenues of $323 million and $262 million for the three months ended December 31, 2016 and 2015, respectively, and $1,107 million and $872 million for the twelve months ended December 31, 2016 and 2015, respectively.
(c)	Includes Daklinza (daclatasvir) revenues of $221 million and $423 million for the three months ended December 31, 2016 and 2015, respectively, and $1,550 million and $1,315 million for the twelve months ended December 31, 2016 and 2015, respectively.
(d)	The Sustiva Franchise includes sales of Sustiva and revenue from sales of bulk efavirenz included in the combination therapy, Atripla. Includes alliance revenue of $217 million and $273 million for the three months ended December 31, 2016 and 2015, respectively, and $934 million and $1,096 million for the twelve months ended December 31, 2016 and 2015, respectively.
(e)	Includes alliance revenue of $7 million for the three months ended December 31, 2015 and $604 million for the twelve months ended December 31, 2015. BMS's U.S. commercialization rights to Abilify expired in April 2015.
(f)	Represents all other products, including those which have lost exclusivity in major markets, over the counter brands and royalty-related revenue.

	Note: 2015 year-to-date revenues of new and inline brands grew 41% excluding Abilify, Baraclude and the Sustiva Franchise.

BRISTOL-MYERS SQUIBB COMPANY

U.S. REVENUES

QUARTERLY REVENUES TREND ANALYSIS

(Unaudited, dollars in millions)



	2015														2016														% Change
	1st Qtr		2nd Qtr		6 Months		3rd Qtr		9 Months		4th Qtr		Year		1st Qtr		2nd Qtr		6 Months		3rd Qtr		9 Months		4th Qtr		Year		Qtr vs. Qtr	YTD vs. YTD
Oncology
Empliciti	$	—	$	—	$	—	$	—	$	—	$	3	$	3	$	28	$	33	$	61	$	36	$	97	$	36	$	133	**	**
Erbitux	157		165		322		165		487		—		487		—		—		—		—		—		—		—		—	(100)%
Opdivo	38		107		145		268		413		410		823		594		643		1,237		712		1,949		715		2,664		74%	**
Sprycel	181		205		386		215		601		228		829		210		233		443		259		702		267		969		17%	17%
Yervoy	181		136		317		121		438		164		602		199		179		378		222		600		202		802		23%	33%
Cardiovascular
Eliquis	200		243		443		245		688		335		1,023		468		444		912		512		1,424		539		1,963		61%	92%
Immunoscience
Orencia^(a)	259		310		569		330		899		372		1,271		321		401		722		387		1,109		423		1,532		14%	21%
Virology
Baraclude	46		37		83		25		108		27		135		17		15		32		17		49		17		66		(37)%	(51)%
Hepatitis C Franchise^(b)	—		—		—		111		111		212		323		259		294		553		192		745		82		827		(61)%	**
Reyataz Franchise	143		157		300		149		449		142		591		120		122		242		125		367		117		484		(18)%	(18)%
Sustiva Franchise^(c)	234		258		492		280		772		269		1,041		228		227		455		234		689		212		901		(21)%	(13)%
Neuroscience
Abilify	508		67		575		18		593		7		600		—		—		—		—		—		—		—		(100)%	(100)%

Mature Products and All Other^(d)	97		152		249		117		366		94		460		93		97		190		94		284		95		379		1%	(18)%

Total^(e)	$	2,044	$	1,837	$	3,881	$	2,044	$	5,925	$	2,263	$	8,188	$	2,537	$	2,688	$	5,225	$	2,790	$	8,015	$	2,705	$	10,720	20%	31%



**	In excess of +/- 100%
(a)	Includes Orencia SubQ revenues of $203 million and $174 million for the three months ended December 31, 2016 and 2015, respectively, and $693 million and $567 million for the twelve months ended December 31, 2016 and 2015, respectively.
(b)	Includes revenues of Daklinza (daclastasvir) only, which was launched in the U.S. in the third quarter of 2015.
(c)	The Sustiva Franchise includes sales of Sustiva, as well as revenue from sales of bulk efavirenz included in the combination therapy, Atripla.
(d)	Represents all other products sold in the U.S., including those which have lost exclusivity.
(e)	Includes United States and Puerto Rico.

BRISTOL-MYERS SQUIBB COMPANY

INTERNATIONAL REVENUES

QUARTERLY REVENUES TREND ANALYSIS

(Unaudited, dollars in millions)



	2015														2016														% Change
	1st Qtr		2nd Qtr		6 Months		3rd Qtr		9 Months		4th Qtr		Year		1st Qtr		2nd Qtr		6 Months		3rd Qtr		9 Months		4th Qtr		Year		Qtr vs. Qtr	YTD vs. YTD
Oncology
Empliciti	$	—	$	—	$	—	$	—	$	—	$	—	$	—	$	—	$	1	$	1	$	5	$	6	$	11	$	17	N/A	N/A
Erbitux	8		4		12		2		14		—		14		—		—		—		—		—		—		—		—	(100)%
Opdivo	2		15		17		37		54		65		119		110		197		307		208		515		595		1,110		**	**
Sprycel	194		200		394		196		590		201		791		197		218		415		213		628		227		855		13%	8%
Yervoy	144		160		304		119		423		101		524		64		62		126		63		189		62		251		(39)%	(52)%
Cardiovascular
Eliquis	155		194		349		221		570		267		837		266		333		599		372		971		409		1,380		53%	65%
Immunoscience
Orencia	141		151		292		154		446		168		614		154		192		346		185		531		202		733		20%	19%
Virology
Baraclude	294		306		600		295		895		282		1,177		274		284		558		289		847		279		1,126		(1)%	(4)%
Hepatitis C Franchise^(a)	264		479		743		291		1,034		246		1,280		168		252		420		187		607		144		751		(41)%	(41)%
Reyataz Franchise	151		146		297		121		418		130		548		101		125		226		113		339		89		428		(32)%	(22)%
Sustiva Franchise^(b)	56		59		115		53		168		43		211		45		44		89		41		130		34		164		(21)%	(22)%
Neuroscience
Abilify^(c)	46		40		86		28		114		32		146		33		35		68		29		97		31		128		(3)%	(12)%

Mature Products and All Other^(d)	542		572		1,114		508		1,622		489		2,111		442		440		882		427		1,309		455		1,764		(7)%	(16)%

Total^(e)	$	1,997	$	2,326	$	4,323	$	2,025	$	6,348	$	2,024	$	8,372	$	1,854	$	2,183	$	4,037	$	2,132	$	6,169	$	2,538	$	8,707	25%	4%



**	In excess of +/- 100%
(a)	Includes Daklinza (daclatasvir) revenues of $139 million and $211 million for the three months ended December 31, 2016 and 2015, respectively, and $723 million and $992 million for the twelve months ended December 31, 2016 and 2015, respectively.
(b)	The Sustiva Franchise includes sales of Sustiva and revenue from sales of bulk efavirenz included in the combination therapy, Atripla.
(c)	Includes revenue from the co-promotional agreement with Otsuka Pharmaceutical Co., Ltd.
(d)	Represents all other products, including those which have lost exclusivity in major markets, over the counter brands and royalty-related revenue.
(e)	When adjusted for foreign exchange impact, total revenues increased 28% for the fourth quarter and increased 7% year to date.

BRISTOL-MYERS SQUIBB COMPANY

SPECIFIED ITEMS

(Unaudited, dollars in millions)



	2015																					2016
	1st Qtr			2nd Qtr			6 Months			3rd Qtr			9 Months			4th Qtr			Year			1st Qtr			2nd Qtr			6 Months			3rd Qtr			9 Months			4th Qtr			Year
Cost of products sold^(a)	$	34		$	25		$	59		$	15		$	74		$	10		$	84		$	4		$	4		$	8		$	7		$	15		$	6		$	21

Marketing, selling and administrative	1			3			4			2			6			4			10			—			—			—			—			—			—			—

License and asset acquisition charges	162			869			1,031			94			1,125			554			1,679			125			139			264			45			309			130			439
IPRD impairments	—			—			—			—			—			160			160			—			—			—			—			—			13			13
Accelerated depreciation and other	—			2			2			15			17			27			44			13			13			26			14			40			43			83
Research and development	162			871			1,033			109			1,142			741			1,883			138			152			290			59			349			186			535

Provision for restructuring	12			28			40			10			50			65			115			4			18			22			19			41			68			109
Divestiture (gains)/losses	(152		)	(8		)	(160		)	(198		)	(358		)	171			(187		)	(269		)	(277		)	(546		)	(13		)	(559		)	—			(559		)
Pension charges	27			36			63			48			111			49			160			22			25			47			19			66			25			91
Written option adjustment	(36		)	—			(36		)	(87		)	(123		)	—			(123		)	—			—			—			—			—			—			—
Litigation and other settlements	14			1			15			—			15			143			158			43			—			43			(3		)	40			—			40
Intangible asset impairment	13			—			13			—			13			—			13			15			—			15			—			15			—			15
Loss on debt redemption	—			180			180			—			180			—			180			—			—			—			—			—			—			—
Royalties and licensing income	—			—			—			—			—			—			—			—			—			—			—			—			(10		)	(10		)
Other (income)/expense	(122		)	237			115			(227		)	(112		)	428			316			(185		)	(234		)	(419		)	22			(397		)	83			(314		)

Increase/(decrease) to pretax income	75			1,136			1,211			(101		)	1,110			1,183			2,293			(43		)	(78		)	(121		)	88			(33		)	275			242

Income tax on items above	(68		)	(116		)	(184		)	43			(141		)	(339		)	(480		)	83			76			159			(3		)	156			(105		)	51

Increase/(decrease) to net earnings	$	7		$	1,020		$	1,027		$	(58	)	$	969		$	844		$	1,813		$	40		$	(2	)	$	38		$	85		$	123		$	170		$	293



(a)	Specified items in cost of products sold are accelerated depreciation, asset impairment and other shutdown costs.

BRISTOL-MYERS SQUIBB COMPANY

RECONCILIATION OF CERTAIN GAAP LINE ITEMS TO CERTAIN NON-GAAP LINE ITEMS

(Unaudited, dollars in millions)



	2015																					2016
	1st Qtr			2nd Qtr			6 Months			3rd Qtr			9 Months			4th Qtr			Year			1st Qtr			2nd Qtr			6 Months			3rd Qtr			9 Months			4th Qtr			Year
Gross Profit	$	3,194		$	3,150		$	6,344		$	2,972		$	9,316		$	3,335		$	12,651		$	3,339		$	3,665		$	7,004		$	3,617		$	10,621		$	3,860		$	14,481
Specified items^(a)	34			25			59			15			74			10			84			4			4			8			7			15			6			21
Gross profit excluding specified items	3,228			3,175			6,403			2,987			9,390			3,345			12,735			3,343			3,669			7,012			3,624			10,636			3,866			14,502

Marketing, selling and administrative	1,029			1,135			2,164			1,176			3,340			1,501			4,841			1,068			1,238			2,306			1,144			3,450			1,461			4,911
Specified items^(a)	(1		)	(3		)	(4		)	(2		)	(6		)	(4		)	(10		)	—			—			—			—			—			—			—
Marketing, selling and administrative excluding specified items	1,028			1,132			2,160			1,174			3,334			1,497			4,831			1,068			1,238			2,306			1,144			3,450			1,461			4,911

Research and development	1,016			1,856			2,872			1,132			4,004			1,916			5,920			1,136			1,266			2,402			1,138			3,540			1,400			4,940
Specified items^(a)	(162		)	(871		)	(1,033		)	(109		)	(1,142		)	(741		)	(1,883		)	(138		)	(152		)	(290		)	(59		)	(349		)	(186		)	(535		)
Research and development excluding specified items	854			985			1,839			1,023			2,862			1,175			4,037			998			1,114			2,112			1,079			3,191			1,214			4,405

Other (income)/expense	(299		)	107			(192		)	(323		)	(515		)	328			(187		)	(520		)	(454		)	(974		)	(224		)	(1,198		)	(87		)	(1,285		)
Specified items^(a)	122			(237		)	(115		)	227			112			(428		)	(316		)	185			234			419			(22		)	397			(83		)	314
Other (income)/expense excluding specified items	(177		)	(130		)	(307		)	(96		)	(403		)	(100		)	(503		)	(335		)	(220		)	(555		)	(246		)	(801		)	(170		)	(971		)



(a)	Refer to the Specified Items schedule for further details.

BRISTOL-MYERS SQUIBB COMPANY

RECONCILIATION OF GAAP TO NON-GAAP EPS

(Unaudited, dollars in millions)



	2015																					2016
	1st Qtr			2nd Qtr			6 Months			3rd Qtr			9 Months			4th Qtr			Year			1st Qtr			2nd Qtr			6 Months			3rd Qtr			9 Months			4th Qtr			Year
Earnings/(loss) before income taxes	$	1,448		$	52		$	1,500		$	987		$	2,487		$	(410	)	$	2,077		$	1,655		$	1,615		$	3,270		$	1,559		$	4,829		$	1,086		$	5,915
Specified items^(a)	75			1,136			1,211			(101		)	1,110			1,183			2,293			(43		)	(78		)	(121		)	88			(33		)	275			242
Earnings before income taxes excluding specified items	1,523			1,188			2,711			886			3,597			773			4,370			1,612			1,537			3,149			1,647			4,796			1,361			6,157

Provision for/(benefit from) income taxes	249			162			411			257			668			(222		)	446			449			427			876			344			1,220			188			1,408
Tax on specified items^(a)	(68		)	(116		)	(184		)	43			(141		)	(339		)	(480		)	83			76			159			(3		)	156			(105		)	51
Provision for income taxes excluding tax on specified items	317			278			595			214			809			117			926			366			351			717			347			1,064			293			1,357

Net earnings/(loss) attributable to BMS used for Diluted EPS Calculation - GAAP	1,186			(130		)	1,056			706			1,762			(197		)	1,565			1,195			1,166			2,361			1,202			3,563			894			4,457
Specified items^(a)	7			1,020			1,027			(58		)	969			844			1,813			40			(2		)	38			85			123			170			293
Net earnings attributable to BMS used for Diluted EPS Calculation excluding specified items - Non-GAAP	1,193			890			2,083			648			2,731			647			3,378			1,235			1,164			2,399			1,287			3,686			1,064			4,750

Weighted-average Common shares Outstanding - Diluted- GAAP	1,676			1,667			1,677			1,678			1,677			1,669			1,679			1,680			1,679			1,679			1,679			1,679			1,680			1,680
Incremental shares Attributable to Share-Based compensation Plans	—			10			—			—			—			12			—			—			—			—			—			—			—			—
Weighted-average Common shares Outstanding - Diluted- Non-GAAP	1,676			1,677			1,677			1,678			1,677			1,681			1,679			1,680			1,679			1,679			1,679			1,679			1,680			1,680

Diluted Earnings/(loss) Per Share - GAAP	$	0.71		$	(0.08	)	$	0.63		$	0.42		$	1.05		$	(0.12	)	$	0.93		$	0.71		$	0.69		$	1.41		$	0.72		$	2.12		$	0.53		$	2.65
Diluted Earnings/(loss) Per Share attributable to specified items	—			0.61			0.61			(0.03		)	0.58			0.50			1.08			0.03			—			0.02			0.05			0.08			0.10			0.18
Diluted Earnings Per Share - Non-GAAP	$	0.71		$	0.53		$	1.24		$	0.39		$	1.63		$	0.38		$	2.01		$	0.74		$	0.69		$	1.43		$	0.77		$	2.20		$	0.63		$	2.83

Effective Tax Rate	17.2		%	311.5		%	27.4		%	26.0		%	26.9		%	54.1		%	21.5		%	27.1		%	26.4		%	26.8		%	22.1		%	25.3		%	17.3		%	23.8		%
Specified items ^(a)	3.6		%	(288.1		)%	(5.5		)%	(1.8		)%	(4.4		)%	(39.0		)%	(0.3		)%	(4.4		)%	(3.6		)%	(4.0		)%	(1.0		)%	(3.1		)%	4.2		%	(1.8		)%
Effective Tax Rate excluding specified items	20.8		%	23.4		%	21.9		%	24.2		%	22.5		%	15.1		%	21.2		%	22.7		%	22.8		%	22.8		%	21.1		%	22.2		%	21.5		%	22.0		%

(a)

Refer to the Specified Items schedule for further details. Effective tax rate on the Specified Items represents the difference between the GAAP and Non-GAAP effective tax rate.

BRISTOL-MYERS SQUIBB COMPANY

SELECTED BALANCE SHEET INFORMATION

(Unaudited, dollars in millions)



	March 31, 2015			June 30, 2015			September 30, 2015			December 31, 2015			March 31, 2016			June 30, 2016			September 30, 2016			December 31, 2016
Cash and cash equivalents	$	6,294		$	4,199		$	3,975		$	2,385		$	2,644		$	2,934		$	3,432		$	4,237
Marketable securities - current	1,313			1,277			1,438			1,885			1,663			1,717			2,128			2,113
Marketable securities - non-current	4,279			4,632			4,627			4,660			3,689			3,281			3,035			2,719
Cash, cash equivalents and marketable securities	11,886			10,108			10,040			8,930			7,996			7,932			8,595			9,069

Short-term borrowings and current portion of long-term debt	(330		)	(755		)	(642		)	(139		)	(106		)	(155		)	(990		)	(992		)
Long-term debt	(7,127		)	(6,615		)	(6,632		)	(6,550		)	(6,593		)	(6,581		)	(5,836		)	(5,716		)
Net cash position	$	4,429		$	2,738		$	2,766		$	2,241		$	1,297		$	1,196		$	1,769		$	2,361



	BRISTOL-MYERS SQUIBB COMPANY
2017 FULL YEAR PROJECTED DILUTED EPS FROM OPERATIONS
	EXCLUDING PROJECTED SPECIFIED ITEMS



	Full Year 2017
	Full Year 2017

	Pre-tax		Tax		After-tax
Projected Diluted Earnings Attributable to Shareholders per Common Share - GAAP					$2.47 to $2.67

Projected Specified Items:
Restructuring, accelerated depreciation and other shutdown costs ⁽¹⁾	0.33		0.11		0.22
Divestiture gains	(0.06	)	(0.02	)	(0.04	)
Research and development license and asset acquisition charges	0.19		0.01		0.18
Pension charges	0.08		0.03		0.05
Litigation and other settlements	(0.28	)	(0.10	)	(0.18	)
Total	0.26		0.03		0.23

Projected Diluted Earnings Attributable to Shareholders per Common Share - non-GAAP					$2.70 to $2.90

⁽¹⁾ Includes items recognized in Research and development and Other (income)/expense.

Note - The above per-share amounts include certain rounding adjustments.

The following table summarizes the company's 2017 financial guidance:

Line item

GAAP

Non-GAAP

Gross margin as a percent of revenue

Approximately 72%-73%

Marketing, selling and administrative expense

Decrease in mid to high-single digits compared to 2016

Research and development expense

Increase in the high-single digits compared to 2016

Effective tax rate

Approximately 21%



The GAAP financial results for the full year 2017 will include specified items, including gains on divestitures, charges associated with downsizing and streamlining worldwide operations, in-process research and development (IPRD), license and asset acquisition charges, charges related to significant legal proceedings, licensed asset impairments, restructuring and pension charges. The GAAP financial results for 2017 could also include other specified items that have not yet been identified and quantified, including any additional gains or losses from divestitures, license and asset acquisition charges, charges for IPRD and licensed asset impairments, recoveries relating to significant legal proceedings and significant tax events. For a fuller discussion of certain litigation and other matters that could impact full year GAAP results, as well as the use of non-GAAP financial information, see Bristol-Myers Squibb Reports Fourth Quarter 2016 Financial Results, January 26, 2017 including “2017 Financial Guidance” and “Use of non-GAAP Financial Information” therein.

GRAPHIC 4 bmslogoq42016.jpg GRAPHIC begin 644 bmslogoq42016.jpg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end